Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz Invests In Its Unique Antibiotics Offering

CEO Richard Saynor Outlines The Attraction Of Recently-Closed Deal With GSK

Executive Summary

In the wake of a major deal to acquire GlaxoSmithKline’s cephalosporins business, Sandoz CEO Richard Saynor has set out why the company’s unique position means that antibiotics are an important area for investments, in an exclusive interview with Generics Bulletin.

You may also be interested in...



Celltrion Takes Trio Of GGB Awards In Milan

Celltrion has taken home three awards while Sandoz and Dr Reddy’s have walked away with two prizes each, after winners were announced at the Global Generics & Biosimilars Awards 2021, held in Milan, Italy, on 10 November.

Sandoz ‘Bucks Trend’ With Completion Of GSK Cephalosporins Deal

Sandoz has completed the acquisition of GSK’s cephalosporin antibiotics business which includes the Zinnat, Zinacef and Fortum brands in more than 100 markets. Commenting as the deal closed, Sandoz CEO Richard Saynor emphasized the importance of investing in antibiotics. 

EU Pharma Strategy Will Remove Barriers And Bolster Competition

The European Commission’s newly-published Pharmaceutical Strategy features a range of proposals related to generics and biosimilars, including “targeted policies” to improve competition, remove barriers and increase uptake.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB151407

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel